Genesis Orthopedics and Sports Medicine Delivering Elite Level Sports Medicine and Orthopedic Care to the Most Underserved Part of the Community

Genesis Orthopedics and Sports Medicine, (one of the fastest-growing privately held companies in the country is serving one of the most underserved segments in sports medicine and orthopedics) which was recently named to the Inc. 5000 Fastest-Growing Privately Held Companies, is delivering the same quality of service that pro athletes receive to those who can’t afford it through its proprietary care delivery model.

Genesis Orthopedics and Sports Medicine is led by Dr. Hythem Shadid, one of the top names in Sports Medicine and Orthopedics and former Team Physician for U.S. National Soccer Teams.  Dr. Shadid and Genesis serve patients in eight locations across Chicagoland.

Genesis Orthopedics and Sports Medicine has established a new model where all people are valued and treated, regardless of economic status, with ethical pricing, and where surgery is seen as a last resort and not a preferred revenue source.

Reimbursement rates are low for Medicaid and Medicare in Illinois –  only 1 percent of orthopedic practices accept patients who are on Medicaid or Medicare. Conversely, Genesis’ patient base is made up of approximately 75 percent Medicaid and Medicare patients. “With our care delivery model, we’ve managed to do it sustainably, while still organically growing each year with new offices across Chicagoland to serve even more effectively,” said Andrew Shadid, CEO of Genesis Orthopedics & Sports Medicine.

Dr. Hythem Shadid, President and Orthopedic Surgeon at Genesis Orthopedics & Sports Medicine, is a board-certified orthopedic surgeon with the American Board of Orthopedic Surgeons and has been in practice since 1994. He is a distinguished researcher and specializes in advanced knee, hip, and shoulder conditions. He previously served as the team orthopedic physician for the men’s and women’s U.S. national soccer teams.

“Equity in healthcare is extremely important to us, so we’re dedicated to ensuring that our practice is welcoming to everyone, regardless of income, wealth, or insurance status. Everyone is welcome at Genesis, and we’re excited for what the future holds as we press forward into new possibilities for serving those in orthopedic need,” said Dr. Shadid.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”